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IMPORTANCE The clinical phenotype and certain predisposing genetic mutations that confer
increasedmelanoma risk are established; however, no consensus exists regarding optimal
screening for such individuals. Early identification remains themost important intervention in
reducingmelanomamortality.
OBJECTIVE To evaluate the impact of full-body examinations every 6months supported by
dermoscopy and total-body photography (TBP) on all patients and sequential digital
dermoscopy imaging (SDDI), when indicated, on detecting primary melanoma in an
extreme-risk population.
DESIGN, SETTING, AND PARTICIPANTS Prospective observational study from February 2006 to
February 2011, with patients recruited from SydneyMelanoma Diagnostic Centre and
Melanoma Institute Australia who had a history of invasive melanoma and dysplastic nevus
syndrome, history of invasive melanoma and at least 3 first-degree or second-degree relatives
with prior melanoma, history of at least 2 primary invasive melanomas, or a CDKN2A or CDK4
genemutation.
EXPOSURES Six-month full-body examination compared with TBP. For equivocal lesions,
SDDI short term (approximately 3 months) or long term (6months), following established
criteria, was performed. Atypical lesions were excised.
MAIN OUTCOMES ANDMEASURES Newprimarymelanoma numbers, characteristics, and
cumulative incidence in each patient subgroup; effect of diagnostic aids on newmelanoma
identification.
RESULTS In 311 patients with a median (interquartile range [IQR]) follow-up of 3.5 (2.4-4.2)
years, 75 primary melanomas were detected, 14 at baseline visit. Median (IQR) Breslow
thickness of postbaseline incident melanomas was in situ (in situ to 0.60mm). Thirty-eight
percent were detected using TBP and 39%with SDDI. Five melanomas were greater than 1
mmBreslow thickness, 3 of which were histologically desmoplastic; the other 2 had nodular
components. The benign tomalignant excision ratio was 1.6:1 for all lesions excised and 4.4:1
for melanocytic lesions. Cumulative risk of developing a novel primary melanomawas 12.7%
by year 2, with new primary melanoma incidence during the final 3 years of follow-up half of
that observed during the first 2 years (incidence density ratio, 0.43 [95% CI, 0.25-0.74];
P = .002).
CONCLUSIONS AND RELEVANCE Monitoring patients at extreme risk with TBP and SDDI
assisted with early diagnosis of primary melanoma. Hypervigilance for difficult-to-detect
thick melanoma subtypes is crucial.
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M elanoma incidence is increasing annually inAustra-lia,where it is the fourthmost commoncancer.1 Themost importantpredictorsof futuremelanoma,apart
from possession of a predisposing high-penetrance germline
mutation, are a history of melanoma and multiple atypical
nevi.2-4 Guidelines recommend that individuals at highest
risk be selected for closer surveillance.5 Whereas encourag-
ing vigilance and self–skin examination is important, there
is increasing evidence that interventions such as dermos-
copy, sequentialdigitaldermsocopic imaging (SDDI), andbase-
line total-body photography (TBP) can aid early detection of
melanoma.6-8
Meta-analysis indicates improved diagnosis of mela-
nomawithdermoscopicvsnakedeyeevaluation in the clinic.9
TheuseofSDDIenhancesearlierdetectionof featurelessmela-
nomasand reduces excisionsof benignpigmented lesions.10,11
Dermatologistswithaccess toSDDIdemonstrate improvedsen-
sitivity and specificity of melanoma diagnosis when com-
pared with dermatologists using dermoscopy only in their
practice.12 Combining SDDI and TBP improves diagnosis of
clinically featureless and de novo melanomas that might be
missed with dermoscopy alone.13
We recruited a cohort at extreme high risk of melanoma
and evaluated the impact of full-body examinations every
6 months supported by dermoscopy and TBP, with SDDI
where indicated, on the detection of primary melanoma in
this population.
Methods
Study Population
The study was approved by the ethics committee of Royal
Prince AlfredHospital, with recruitment bywritten informed
consent. Patients (≥18 years of age) fulfilling at least 1 of the
following 4 inclusion criteria were recruited from outpatient
clinics of the Sydney Melanoma Diagnostic Centre and the
Melanoma Institute Australia.
Group 1: Personal history of at least 1 invasivemelanoma and
dysplastic nevus syndrome (DNS). Dysplastic nevus syn-
drome was defined as at least 100 nevi, at least 6 of which
showed atypical dermoscopic features consistent with dys-
plastic nevus as previously described,14(pp79-128) and at least 1
of which was at least 8 mm in greatest dimension.
Group 2: Personal history of at least 1 invasivemelanoma and
a familyhistoryof at least 3 first-degreeor second-degree rela-
tives with a confirmed history of malignant melanoma.
Group 3: Personal history of at least 2 primary invasivemela-
nomas,with at least 1 occurring in the 10years prior to recruit-
ment for patients with only 2 melanomas.
Group4: ConfirmedCDKN2A (OMIM600160) orCDK4 (OMIM
123829) gene mutation (the highest-penetrance susceptibil-
itygenemutations formelanoma).Nohistoryof invasivemela-
noma was required for this group, although 12 of 17 patients
had such a history.
Certain patients satisfied more than 1 inclusion criterion
and were analyzed in each category. Family history was vali-
dated by recruitment, where necessary, to the University of
Sydney GenoMEL study center at Westmead Millennium
Institute,15 from which, in turn, confirmed CDKN2A muta-
tion carriers were referred to the melanoma high-risk clinic.
All participants in category 4 carried confirmed pathogenic
CDKN2Amutations; none had CDK4mutations.15
Study Design
Key patient data were recorded at each visit and stored on a
purpose-builtFilemakerProdatabase (Filemaker Inc).Eachpa-
tient was reviewed on a 6-month basis by a dermatologist
(F.J.M., P.G., N.K.H., K.H.) or, in a small proportion of visits,
by dermatology registrars.
Initial Visit
Baselinedataobtained includedage, sex,Fitzpatrick skin type,
eye color, hair color, and childhood freckling history. The at-
tending physician performed a mole count documenting the
patient’s total nevus and dysplastic nevus count. Each pa-
tient underwent a full skin examination and contact dermo-
scopic evaluation of suspicious lesions using aHeineDelta 20
dermatoscope (Heine Optotechnik). Lesions of concern were
excised, referred for SDDI, or compared with images if previ-
ously monitored.
SDDI
Macular or slightly raisedmelanocytic lesions considered sus-
picious because of dermoscopic appearance or history of
change but lacking any positive features of melanoma were
monitored using short-term SDDI (SolarScan, Polartechnics
Ltd) as previously described.11 A baseline dermoscopic image
was repeatedat 3monthswithexcisionof lesions showingany
morphological change, as previously described.16 Substan-
tially raised suspicious lesions were excluded from SDDI and
excised. For melanocytic lesions undergoing SDDI over lon-
ger intervals (long-termmonitoring≥6months), suchas inpa-
tients with multiple dysplastic nevi, lesions were excised ac-
cording to the clinically significantmorphological changes as
previously described.17,18 Long-term SDDI was performed on
less suspicious atypical nevi (compared with those undergo-
ing short-termSDDI) or in somenevi previouslymonitoredby
short-term SDDI.
TBP
Each patient underwent baseline digital TBP following stan-
dard protocols, according to which between 12 and 24 high-
resolution digital photographs of their skin surface were
recorded19 (Polartechnics Pty Ltd andMoleMap Pty Ltd). The
photographswereprovidedonaDVDto thepatient, andacopy
of the images was stored. Patients were instructed in the use
of TBP and asked to perform a full self–skin examination at 3
monthsandagain thedaybefore their6-month follow-upvisit.
Follow-up Visits
At each follow-up visit, patients were initially asked about
changes that theyhadnoted eitherwith orwithout TBP assis-
tance. Patients then underwent a full clinical and dermo-
scopic skin examination. The clinician then compared thepa-
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tient with baseline TBP images. Any lesion noted as changed
from baseline was recorded. If the lesion was also earmarked
during the clinical and/or dermoscopic examination as being
of concern, it was coded as “detected with the aid of TBP.” If
the lesion had not been previously earmarked, it was coded
as “detected exclusively with TBP.”
Again, lesionsof concernwereexcisedor referred for SDDI
(short term or long term). For all lesions excised, the reason
for the decisionwas recorded: (1) excised only because of pa-
tient request, (2) self-detected without TBP, (3) self-detected
with TBP, (4) clinician detected without TBP, (5) clinician de-
tectedwith aid of TBP, (6) clinician detected exclusively with
TBP, (7) change under short-term SDDI, or (8) change under
long-term SDDI.
Statistical Methods
Datawereexpressedas frequencies (percentages) for categori-
cal variables and as mean and standard deviation or median
and interquartile range (IQR) for normally and nonnormally
distributed continuous variables, respectively. A cumulative
incidence curve of the time to first newmelanoma event dur-
ing the follow-up period was calculated with the Kaplan-
Meier method.20 eFigure 1 (in Supplement) shows the num-
ber at risk at the beginning of each year of follow-up (ie, the
number still under follow-up [not censored] who had not yet
experienced an event).
For multiple-event analysis, a Poisson regression model
usinggeneralizedestimatingequations21(pp162-168)wasusedwith
2timeintervalsperperson:0to2yearsfromregistration(ie,early
[0-2]) and after 2 years (ie, late [>2-5]). Themodel used an off-
set to adjust for patient exposure within each interval and an
exchangeable correlation structure between intervals.
Median follow-up timewas obtained byusing the reverse
Kaplan-Meier method, in which deaths were treated as cen-
soredandcensoredobservationsas failures.22ThePoissongen-
eralized estimating equations analysis produced an inci-
dencedensity ratio (analogoustothehazardratio) that reflected
the relative change in event rate per unit time for late (after 2
years) vs early (within 2years) incidenceofnewprimarymela-
noma. SAS software, version 9.3 (SAS Institute), was used for
the analysis.
Results
Baseline Demographic Characteristics
A total of 311 patientswere recruited between 2006 and 2009.
Of these, 219hadahistoryof invasivemelanomaandDNS(DNS
cohort); 52, ahistoryof invasivemelanomaand3ormore first-
degreeor second-degree relativeswithmelanoma (strong fam-
ily history cohort); 146, a history of multiple previous pri-
mary invasive melanomas (multiple primary melanomas
cohort); and 17, a documented CDKN2A genemutation (gene
mutation carrier cohort). The median (range) age at baseline
was 53 (21-85) years (Table 1).
Ten patients did not attend as per protocol after baseline
assessment, 7 of whom were lost to follow-up. There was no
statistical difference in follow-up duration for the 4 groups,
with a median follow-up for the study population as a whole
of 41.8 months (3.5 years) (IQR, 29.0-50.8 months [2.4-4.2
years]).Ninepatientsdiedduringthecourseof thestudy,7 from
metastatic melanoma, of whom only 1 developed a new pri-
marymelanomaduring the study period. In this latter case, it
was not possible to determine whether metastases devel-
oped from the pretrial or trial melanoma.
Fitzpatrick skin typewasalso consistent across eachof the
studygroups.Approximately two-thirdsofpatientswereFitz-
patrick skin type I or II. Only 2 patients (0.6%) were skin type
IV, andnonewere V or VI (Table 1). Approximately two-thirds
of patients (70%) had 100 or more nevi at baseline counting,
whereas approximatelyone-third (36%)had200ormorenevi.
Lesions Excised
During the studyperiod, 770 lesionswere excised from thepa-
tient cohort (Table 2), ofwhich 291 (38%)weremalignant, for a
benign tomalignant ratio of 1.6:1 for all lesions. The benign to
malignant ratioswere2.2:1 in theDNScohort, 1.8:1 in thestrong
familyhistory cohort, 1.1:1 in themultiple primarymelanomas
cohort, and1.6:1 in thegenemutationcarrier cohort.Of the770
excised lesions, 441 were melanocytic, including 82 melano-
mas, representing a 4.4:1 benignmelanocytic tomelanoma ra-
tio. Of the 359 benign melanocytic lesions excised, 251 (70%)
were reported as dysplastic nevi. Of the 291 excisedmalignant
skin lesions, 209werenonmelanomaskin cancers, comprising
143basalcellcarcinomas,35squamouscellcarcinomas,29squa-
mouscellcarcinomasinsitu,and2keratoacanthomas.Thebasal
cell carcinoma to squamous cell carcinomas ratio was 2.2:1 in
the study population overall.
A high proportion of themelanoma-associated nevi were
dysplastic (37 of 38 [97%]). Of the nevi excised and not asso-
ciated with melanoma, 251 of 337 (74%) were dysplastic.
The 82melanomasdetectedduring the study included 75
primary tumors and 7 locally recurrent or cutaneous metas-
tases (Table 3). Fifty-oneof theprimarymelanomas (68%) oc-
curred in the 179 men, compared with 24 primary melano-
mas (32%) in the 132 women. The median (IQR) Breslow
thickness for all primary melanomas identified, including at
baseline, was in situ (in situ to 0.60 mm). Body site and his-
tological subtype are detailed in Table 3.
Fourteenprimarymelanomaswere identified at the base-
line visit. Sixty-one additional primary melanomas diag-
nosedduring follow-upmonitoringvisits (Table 3)were found
in 48 patients, 74% of whom had multiple primary melano-
mas and 67%, 16%, and 5% in the DNS, strong family history,
and gene mutation carrier cohorts, respectively. The overall
rate ofmelanomas identified during follow-up per study year
was 0.08, with the highest rate in themultiple primarymela-
noma cohort (0.11), followed by the strong family history co-
hort (0.08), DNS cohort (0.07), and the genemutation cohort
(0.06), allowing for the fact that certain patients were in-
cluded inmore than 1 subgroup.Themedian (range) time from
baselinevisit toprimarymelanomadetectionwas 17.9months
(2.9-53.2 months).
Thirty-eightpostbaseline incidentmelanomas (62%)were
identified onpathological analysis as nevus-associated (junc-
tional n = 23, with 22 dysplastic and 1 nondysplastic; 15 com-
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pound, all ofwhichwere dysplastic), comparedwith 23 (38%)
developingdenovo. Themedian (IQR)Breslow thicknesswas
in situ (in situ to0.60mm)whenonlymelanomasdetected fol-
lowing thebaseline visitwere considered. Five of the 61mela-
nomas diagnosed after the baseline visit had a Breslow thick-
ness of greater than 1 mm (Table 4). Three of the 5 thick
melanomas were desmoplastic (none associated with a ne-
vus) andoccurred in 2 siblings (eFigure 2 in Supplement). Two
of theseweremorphologicallyamelanoticondermoscopy, and
theother, tan. The 2other lesionshadboth superficial spread-
Table 1. Characteristics of Patients at ExtremeHigh Risk ofMelanoma by Subgroupa
Characteristic
All Patients
(N = 311)
DNS and History of
Melanoma
(n = 219)
Strong Family and Personal
History of Melanoma
(n = 52)
Multiple Primary
Melanomas
(n = 146)
Gene Mutation
(n = 17)
Age at baseline, median
(range), y
53 (21-85) 51 (21-77) 50 (27-81) 59 (29-85) 48 (30-81)
Sex, No. (%)
Male 179 (58) 125 (57) 17 (33) 86 (59) 7 (41)
Female 132 (42) 94 (43) 35 (67) 60 (41) 10 (59)
Follow-up, months
Total 11 998 8750 1703 5802 565
Median (range) 41.8 (29.0-50.8) 43.0 (31.2-51.1) 31.9 (24.9-44.3) 45.0 (29.0-52.1) 40.5 (6.2-50.5)
Phenotype, No. (%)
I 49 (16) 34 (16) 8 (15) 24 (16) 3 (18)
II 165 (53) 116 (53) 28 (54) 80 (55) 7 (41)
III 92 (30) 67 (31) 14 (27) 40 (27) 6 (35)
IV 2 (0.6) 1 (0.5) 1 (2) 1 (0.7) 1 (6)
V 0 0 0 0 0
VI 0 0 0 0 0
No value 3 (1) 1 (0.5) 1 (2) 1 (0.7) 0
Eye color, No. (%)
Blue/gray 177 (57) 114 (52) 26 (50) 94 (64) 13 (76)
Hazel/green 97 (31) 77 (35) 19 (37) 34 (23) 2 (12)
Brown 32 (10) 25 (11) 6 (12) 15 (10) 2 (12)
No value 5 (2) 3 (1) 1 (2) 3 (2) 0
Hair color, No. (%)
Red 52 (17) 29 (13) 12 (23) 32 (22) 4 (24)
Blond 137 (44) 102 (47) 19 (37) 59 (40) 8 (47)
Brown 112 (36) 82 (37) 19 (37) 49 (34) 5 (29)
Black 4 (1) 2 (0.9) 0 2 (1) 0
No value 6 (2) 4 (2) 2 (4) 4 (3) 0
Childhood freckling, No. (%)
None 103 (33) 81 (37) 9 (17) 48 (33) 2 (12)
Very few 83 (27) 56 (26) 15 (29) 37 (25) 5 (29)
Few 60 (19) 41 (19) 14 (27) 30 (21) 6 (35)
Some 30 (10) 19 (9) 4 (8) 15 (10) 2 (12)
Many 20 (6) 13 (6) 6 (12) 11 (8) 2 (12)
Very many 12 (4) 8 (4) 3 (6) 4 (3) 0
No value 3 (1) 1 (0.5) 1 (2) 1 (1) 0
Total nevi, No. (%)
0-49 43 (14) 0 7 (13) 38 (26) 3 (18)
50-99 25 (8) 0 8 (15) 19 (13) 6 (35)
100-199 106 (34) 98 (45) 17 (33) 40 (27) 5 (29)
≥200 111 (36) 109 (50) 14 (27) 37 (25) 2 (12)
No value 26 (8) 12 (6) 6 (12) 12 (8) 1 (6)
Nevus count, median (IQR)
Total 167 (104-253) 202 (150-294) 143 (76-225) 112 (38-202) 78 (60-173)
Dysplastic 8 (6-13) 10 (7-15) 6 (3-12) 6 (3-12) 5 (2-7)
Abbreviations: DNS, dysplastic nevus syndrome; IQR, interquartile range.
a Patients may satisfy inclusion criteria for more than 1 subgroup.
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ingandnodularcomponents.Both lesionsweredescribedclini-
cally as amelanotic, although a dermoscopic image was not
available to confirm this. Importantly, of the 6 predomi-
nantly nodularmelanomas detected postbaseline, only 1 had
aBreslowthicknessgreater than1mm.Fourof6of thesenodu-
larmelanomaswereassociatedwithanevus (2dysplastic com-
pound, 2 dysplastic junctional).
Cumulative Incidence
eFigure 1 (in Supplement) shows the cumulative incidence of
newprimarymelanomas for thestudypopulation foreachyear
of the study. Forty-four of the primarymelanomas identified
after thebaselinevisit (72%)werediagnosed in the first 2 years
of follow-up.The curve illustrates an increased cumulative in-
cidence for melanoma in the first 2 years of inclusion in the
Table 2. Melanomas, Nonmelanoma Skin Cancers (NMSCs), and BenignMelanocytic and Nonmelanocytic
Lesions Excised During Follow-up in Total and by Patient Subgroupa
Lesion
No.
All Patients
(N = 311)
DNS and History
of Melanoma
(n = 219)
Strong Family and
Personal History
of Melanoma
(n = 52)
Multiple Primary
Melanomas
(n = 146)
Gene
Mutation
(n = 17)
Melanoma
SSM 25 18 1 16 0
Nodular 6 4 3 4 2
Lentigo maligna
melanoma
1 0 0 1 0
Lentigo maligna (HMF) 9 4 1 8 0
Desmoplastic 3 3 3 3 0
In situ 30 19 3 21 1
Invasive, not classified 1 1 0 1 0
Local recurrence or
cutaneous metastasisb
7 2 0 6 0
Total 82 51 11 60 3
NMSC
BCC 143 93 8 77 3
SCC 35 14 3 23 3
SCC in situ 29 12 5 20 2
Keratoacanthoma 2 0 1 1 0
Total 209 119 17 121 8
Benign melanocytic
Ephelis 3 3 0 1 0
Lentigo 19 14 1 12 1
Lentiginous nevus 5 4 2 1 0
Junctional nevus 19 14 3 10 0
Compound nevus 40 39 5 9 3
Intradermal nevus 21 17 1 7 0
Blue nevus 1 0 0 1 0
Dysplastic junctional
nevus
130 102 12 63 4
Dysplastic compound
nevus
121 108 10 39 3
Total 359 301 34 143 11
Benign nonmelanocytic
Dermatofibroma 12 9 1 8 0
Capillary hemangioma 3 1 2 1 1
Seborrheic keratosis 21 13 1 12 0
Actinic keratosis 21 12 4 13 3
Granuloma 1 0 0 1 0
Inflammatory and/or
pigment incontinence
2 1 0 2 0
Other 53 33 9 25 3
Total 113 69 17 62 7
No pathology report
obtainable
7 6 0 1 0
Total lesions excised 770 546 79 387 29
Abbreviations: BCC, basal cell
carcinoma; DNS, dysplastic nevus
syndrome; HMF, Hutchinson
melanocytic freckle;
NMSC, nonmelanoma skin cancer;
SCC, squamous cell carcinoma;
SSM, superficial spreading
melanoma.
a Patients may satisfy inclusion
criteria for more than 1 subgroup.
bNonprimary melanomas.
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study, with continued new primarymelanoma identification
out to year 5. The risk of new primary melanoma develop-
ment for all patients was 12.7% by year 2 and 18.2% by year 4,
with an incidence of new primarymelanoma during the final
3 years of follow-up noted to be half of that observed during
the first 2 years (incidence density ratio, 0.43 [95% CI, 0.25-
0.74]; P = .002).
Effect of Diagnostic Aids on NewMelanoma Identification
Melanomasdetectedwith SDDI andTBPdidnot differ signifi-
cantly (χ2 test, P = .75) with respect to whether they origi-
nated in nevi or de novo. Twenty-four of the postbaseline in-
cident melanomas (39%) were detected using SDDI (Table 3).
A total of 1697 lesions were monitored by SDDI; that is, 70.7
lesionsweremonitored for eachmelanomadetected.Changes
in 10melanomas (16%)weredetectedon short-termmonitor-
ing whereas 14 (23%) were detected on long-term monitor-
ing. The median (IQR) Breslow thickness for melanomas de-
tected by SDDI was in situ (in situ to 0.15 mm). Twenty-three
of the postbaseline incident melanomas (38%) were excised
after the clinician-detected change on the TBP. The median
(IQR)Breslowthickness formelanomasdetectedwithTBPwas
0.33 (in situ to 0.83 mm). Twenty of the 23 melanomas were
detected with the aid of TBP, whereas 3 were diagnosed ex-
clusively as a result of a change identified on TBP. Ten of the
melanomas diagnosed (16%) were lesions identified dermo-
scopically by the examining physician as suspicious, without
any change noted on TBP or with SDDI. No melanoma diag-
nosed could be exclusively attributed to changes on the TBP
identified by the patient, although 5 melanomas (8%) were
noted by the patient to be changing—without reference to the
TBP—andwere subsequently brought to thephysician’s atten-
tion. Finally, of the 5 melanomas of greater than 1 mm Bres-
low thickness, 2 were self-detected by patients and only 1 of
Table 3. All PrimaryMelanomas Diagnosed During
the Intervention
Characteristic
All Primary
Melanomas
(n = 75)a
Nonbaseline Incident
Primary Melanomas
(n = 61)
Sex, No. (%)
Male 51 (68) 41 (67)
Female 24 (32) 20 (33)
Inclusion criteria,b No. (%)
DNS + melanoma 49 (65) 41 (67)
Strong family
history + melanoma
11 (15) 10 (16)
Multiple primary
melanomas
54 (72) 45 (74)
Gene mutation 3 (4) 3 (5)
Melanomas per year
of follow-up
DNS + melanoma … 0.07
Strong family
history + melanoma
… 0.08
Multiple primary
melanomas
… 0.11
Gene mutation … 0.06
Tumor site, No. (%)
Head and neck 11 (15) 11 (18)
Trunk 35 (47) 26 (43)
Upper limbs 18 (24) 16 (26)
Lower limbs 11 (15) 8 (13)
Detection time, median
(range), months
… 17.9 (2.9-53.2)
Breslow thickness
Median (IQR)
All In situ (in situ
to 0.60 mm)
In situ (in situ
to 0.60 mm)
TBP detected … 0.33 (in situ
to 0.83 mm)
SDDI detected … In situ (in situ
to 0.15 mm)
No. (%)
In situ 38 (51) 32 (52)
≤1 mm 30 (40) 24 (39)
>1 mm 7 (9) 5 (8)
Nevus associated, No. (%)
Yes … 38 (62)
No … 23 (38)
(continued)
Table 3. All PrimaryMelanomas Diagnosed During
the Intervention (continued)
Characteristic
All Primary
Melanomas
(n = 75)a
Nonbaseline Incident
Primary Melanomas
(n = 61)
Histological subtype, No. (%)
Lentigo maligna 9 (12) 8 (13)
Lentigo maligna melanoma 1 (1) 1 (2)
In situ 30 (40) 25 (41)
SSM 25 (33) 17 (28)
Nodular 6 (8) 6 (10)
Desmoplastic 3 (4) 3 (5)
Invasive, not histologically
classified
1 (13) 1 (2)
Excision and detection
reason,c No. (%)
Excision reason unclear … 0
Excised at patient’s
request
… 0
Excised after self-
detection without TBP
… 5 (8)
Excised after self-
detection with TBP
… 0
Excised after clinician
detection without TBP
… 10 (16)
Excised after clinician
detection with TBP
With the aid of TBP … 20 (33)
Exclusively with TBP … 3 (5)
Excised because of change
on lesion monitoring
Short-term monitoring … 10 (16)
Long-term monitoring … 14 (23)
Abbreviations: IQR, interquartile range; SDDI, sequential digital dermoscopy
imaging; SSM, superficial spreadingmelanoma; TBP, total-body photography.
a The categories of melanomas per year of follow-up, detection time, method,
and reason for detection were relevant for nonbaseline incident primary
melanomas only.
b Patients may satisfy inclusion criteria for more than 1 subgroup.
c Certain melanomas were detected with more than 1 method.
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the 5 was detected with the aid of TBP. Of the 6 predomi-
nantly nodularmelanomas detected postbaseline, 3 were de-
tected with the aid of TBP, 2 were detected without TBP, and
1 was self-detected.
When patients with DNS were compared with patients
withoutDNS, therewasno significant difference between the
proportion of postbaseline incident melanomas detected by
TBP (15 of 41 [37%] in the DNS group vs 8 of 20 [40%] in the
non-DNS group; χ2 P = .80) or SDDI (17 of 41 [41%] in the DNS
group vs 7 of 20 [35%] in the non-DNS group; χ2 P = .63). Fi-
nally, therewasno significant difference between thepropor-
tion of postbaseline incident melanomas associated with a
nevus in the DNS group (28 of 41 [68%]), compared with the
non-DNS group (10 of 20 [50%]; χ2 P = .17).
Discussion
Patients with a history of melanoma have a 9-fold increased
risk of developing a new primary melanoma compared with
the general population.23 This risk is further amplified in pa-
tientswithmelanomawhohavemultipledysplasticnevi, ahis-
toryofmultipleprimarymelanomas, 3ormore first-degree rela-
tiveswithmelanoma,or apredisposinggenemutation.2,15,24,25
Toourknowledge, this study is the first toprospectively follow
apatient cohort at extremehigh riskofmelanomawith thepri-
mary aimofdetermining the relative efficacyof diagnostic in-
terventions.
Our study’s inclusion criteria generated patients at ex-
treme melanoma risk, hence the high rate of melanomas de-
tected (75 new primary melanomas in 311 individuals over a
median 3.5-year period).Other studieshaveprospectively fol-
lowedpopulations at increasedmelanoma risk.Haenssle et al7
detected 127 melanomas in 688 patients over 10 years using
nakedeye,dermoscopicanalysis,andSDDI.Theirpatientpopu-
lationwas at increased risk, butnot all patientswerehigh risk.
Malvehy and Puig26 focused on high-risk patients (45% of
whomhadapriormelanoma), identifying98melanomas from
1152 lesions excised in 618 patients monitored over 10 years
with combined SDDI and TBP surveillance.6 Our study also
demonstratedhigh ratesofnonmelanomaskincancer ina rela-
tively young melanoma-prone population (median age, 53
years),with72%(209of291)ofbiopsiedmalignant lesionsdem-
onstrating nonmelanoma skin cancer.
Although the subgroups in our study were not mutually
exclusive, the number of new melanomas per year of fol-
low-up was highest in patients possessing a personal history
of multiple primary invasivemelanoma. In Australia, 1 study
estimated the 10-year risk for developing a second primary
melanoma as 12.7%, and for those who had 2 primary mela-
nomas, the estimated 10-year risk of developing a third was
28%.27 Ferrone et al24 calculated an estimated 11.4% cumula-
tive risk of second primary melanoma within 5 years in pa-
tients with a history of melanoma.
The cumulative incidence of postbaseline incident mela-
nomasdiagnosedwassignificantlyhigher in the first 2years fol-
lowing inclusion despite standard 6-monthly reviews stretch-
ing out to 5 years. We do not report our incidence from first
melanoma but rather from entry into our intervention. In pre-
vious studies observing patients with multiple primary mela-
nomas, 51% to 59% of subsequent primarymelanomas identi-
fied occurred within the first year following initial melanoma
diagnosis, althoughthesepercentagesmustbeevaluated in the
contextof theshortdurationof follow-upinthesestudies.23,28,29
Identifying a preponderance of subsequentmelanomas in the
initial years followingmelanomadiagnosis is anobservation in
part attributed to increased surveillance after diagnosis. Alter-
natively, thosemelanomasmayhavebeenpresentat initial sur-
veillance but without features of melanoma and were there-
foreonlydiagnosablebysubsequentchange identifiedonSDDI
or noted from comparisons with baseline TBP.
Ninety-one percent of postbaseline incident melanomas
excised in this cohortwere thinmelanomas of nomore than 1
mmBreslow thickness. Amedian Breslow thickness of in situ
confers an optimal prognosis formost of themelanomas that
were excised. It iswell documented that subsequentmelano-
mas in patients withmultiple primarymelanomas tend to be
thinner at diagnosis than the patient’s first melanoma.23,28,29
Body site location of melanomas detected in our high-risk
population showed a similar body site distribution (primarily
on the limbs in women and the trunk in men) and histologi-
cal subtype (superficial spreading melanoma and melanoma
in situmost common) compared withmelanomas diagnosed
in the general population.30
All 5 melanomas more than 1 mm thick detected were di-
agnostically challenging because of lack of pigment or rare
pathological subtypes. Whereas 8% of the melanoma sub-
types inour studywerenodular and4%desmoplastic, no such
lesionswere reported in the Spanish cohort, inwhich allmela-
nomas detectedwere 1mmor less.6 Our findings demonstrate
the need for high awareness of raremelanoma subtypes in ex-
treme high risk populations. Desmoplastic melanoma is fre-
quently diagnosed late because of absent pigmentation and
minimalspecific identifyingfeatures.31Hypervigilancefornodu-
lar lesions using dermoscopic criteria32 with prompt biopsy of
longstanding or changing atypical lesions is vital.
Table 4. Melanomas Diagnosed During Follow-up (Postbaseline Incident) Measuring Greater Than 1Millimeter
Breslow Thickness
Breslow thickness, mm Histopathologic Subtype Dermoscopic Appearance Location
21.0 Desmoplastic Amelanotic Left buttock
8.5 Desmoplastic Amelanotic Right upper arm
1.6 Desmoplastic Tan colored Nose
2.3 SSM and nodular Not able to confirm Right neck
1.4 SSM and nodular Not able to confirm Left shoulder
Abbreviations: IQR, interquartile
range; SDDI, sequential digital
dermoscopy imaging; SSM,
superficial spreadingmelanoma.
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Only 8.2% of melanomas were self-detected by patients;
however, 2 of 5 thick melanomas (>1 mm) and 1 of 6 nodular
melanomaswere self-detected. Importantly, inour study,only
1 of 6 postbaseline incident nodular melanomas had a Bres-
low thickness greater than 1 mm, indicating that these rap-
idly growing tumors were detected early using our protocol.
We did not assess patients’ compliance with TBP self-
examinationduring the trial.However, following the trialwith
the samecohort under the sameexaminationprotocol, 46.6%
ofpatients undertook self–skin examinationwithTBPprior to
their consultationand71.7%reportedTBPself-examinationat
least once during the previous 12months (interim analysis of
an ongoing study).
In the present study, 39% of melanomas were diagnosed
eitherexclusivelyoraidedbySDDI.Thiscompareswith the25%
(32of 127)ofmelanomasthatweredetectedexclusivelybySDDI
byHaenssleetal7andthe61%(60of98)ofmelanomasthatwere
identified by SDDI by Salerni et al6 in their high-risk popula-
tions.There is increasinguseofTBP inacademicpigmented le-
sion clinics but few studies demonstrating its efficacy as a
screening adjunct for melanoma.33 In this extreme-risk popu-
lation, 38%ofmelanomaswerediagnosedeither exclusivelyor
aidedbyTBP.ThemedianBreslowthicknesswasinsituformela-
nomas diagnosedwith the aid of either SDDI or TBP.
There are certain limitations to this study. Many patients
satisfied inclusioncriteria formore than1subgroup, sowewere
unable to test for differences in characteristics or outcomes
across nonmutually exclusive groups. Although the nature of
the study precluded a control arm, comparison of surrogate
markers such as benign to malignant ratio and median Bres-
low thickness compares favorablywithother studies. It is pos-
sible that skin cancer incidencewas underestimated because
of excisions by practitioners outside our clinic, although ev-
ery effort was made to capture these events. It is also recog-
nized that the study design includes a greater time allocation
forTBPcomparativeexamination than isprovided for in a rou-
tine clinic setting. Approximately one-third of study patients
hadmore than 200nevi,monitoringofwhich is time consum-
ing and challenging for both patients and physicians. It could
be argued that this study in part demonstrates the value of al-
locating additional clinic time for examination of patients at
higher risk. There were few nonattendances, with most pa-
tients expressing high levels of satisfaction with the service.
Finally, thenevus-associatedmelanomaswere reported from
the synoptic histopathology reports. Because the focus of this
research was early detection of primary melanoma, histo-
pathological review of all excised lesions was not under-
taken.Whereas theremay be difficulty in distinguishing true
dysplastic nevi within melanoma in some cases, the diagno-
sis of melanoma is not in doubt.
Conclusions
Our study highlights the diagnostic importance of both TBP
and SDDI in the follow-up of high-risk patients for primary
melanoma. Despite this, hypervigilance for difficult-to-
detect thick melanoma subtypes is crucial.
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